
Jan Witowski
@janwitowski
CEO & co-founder at @Ataraxis_AI. MD, PhD. Personalizing cancer treatment. Previously @nyugrossman @harvardmed
ID: 56081214
http://ataraxis.ai 12-07-2009 12:24:18
869 Tweet
1,1K Followers
1,1K Following



False positives and unnecessary biopsies frequently arise from mammography screening for breast cancer. A new study using #AI of MRI scans shows the potential for much improvement science.org/doi/10.1126/sc⦠Science Translational Medicine Jan Witowski Krzysztof Geras New York University NYU Grossman School of Medicine and colleagues


A study led by Jan Witowski and Krzysztof Geras employed #DNNs to develop an #AI model for detecting #breastcancer in dynamic contrast-enhanced MRI scans. The model matches the accuracy of experts and could reduce unnecessary biopsies. nvda.ws/3EgGYjR



SAM: Segment Anything Model from FAIR. Foundation model for image segmentation. Demo: segment-anything.com/demo Blog: ai.facebook.com/blog/segment-a⦠Paper: ai.facebook.com/research/publi⦠Code: github.com/facebookresear⦠Dataset: SA-1B , 11 million image, 1 billion masks ai.facebook.com/datasets/segmeā¦

I-JEPA: Efficient method for Self-Supervised Learning of image features. No need for data augmentation, just masking. Joint embedding predictive architecture, not generative. And it's open source, of course. Blog: ai.facebook.com/blog/yann-lecu⦠Paper: arxiv.org/abs/2301.08243 Code &

Itās time to use AI to help cancer patients get truly personalized treatment! To solve this, I founded Ataraxis AI with Krzysztof Geras. Ataraxis is an AI precision medicine company building a new era of tools for better treatment selection, starting with Ataraxis Breast:

āIf you donāt benefit from chemotherapy, you want to avoid it.ā Our CEO Jan Witowski shared with Forbes' Alex Knapp how Ataraxis Breast enables providers to recommend more precise, effective treatmentsāhelping patients avoid unnecessary chemotherapyāand more.


We are coming to NeurIPS! Joe Cappadona will present results of our novel approach to training foundation models for digital pathology. This research goes beyond simply scaling model/data size, and led us to develop Kestrel, the model behind Ataraxis Breast. Come see us!




Big personal update! As of 3/1, Iāve joined Ataraxis AI ā a startup I co-founded in 2022 ā full-time as Chief Scientific Officer. We recently raised a $20.4M Series A, and are now building a frontier AI lab to push the boundaries of personalized oncology treatment. 1/


We are at #ASCO25 this weekend! Jan Witowski will be presenting the results from our Ataraxis Breast clinical validation study--stop by to learn how our multi-modal AI and foundation models help personalize breast cancer treatment.


